HIGHLIGHTS
- who: Ruisong Ye from the Department of Medicine, University of Tennessee Health Science Center, S Manassas St, Memphis, TN, USA have published the article: CRISPR/Cas9 targeting of GPRC6A suppresses prostate cancer tumorigenesis in a human xenograft model, in the Journal: (JOURNAL)
- what: The authors examined the function of human GPRC6A in prostate cancer progression in_vitro and in_vivo. In prior studies the authors show that ligand-mediated activation of GPRC6A is coupled to ERK and AKT phosphorylation . This study shows that by activating GPRC6A, signaling via ERK, AKT, and mTOR is increased in prostate cancer . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.